History
Documents created during the development process.
Background information
-
-
Appendix A: decision paper presented to the Institute's Guidance Executive
-
Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 110 KB)
-
-
TA215 Pazopanib for the first-line treatment of renal cell carcinoma -Appendix A: provisional matrix of stakeholders
-
-
TA215 Pazopanib for the first-line treatment of renal cell carcinoma: Appendix B - proposal paper presented to the Institute's Guidance Executive
-
-
TA215 Renal cell carcinoma (first line metastatic) - pazopanib: press release information
-
Download PDF version
-
2011/030 NICE recommends a new treatment for kidney cancer (PDF 82 KB)
Renal cell carcinoma (first line metastatic) - pazopanib: Equality Impact Assessment form
-
Renal cell carcinoma (first line metastatic) - pazopanib: Equality Impact Assessment form
-
Renal cell carcinoma (first line metastatic) - pazopanib: final appraisal determination
-
Renal cell carcinoma (first line metastatic) - pazopanib: final appraisal determination
-
Renal cell carcinoma (first line metastatic) - pazopanib: final appraisal determination guidance
-
-
Renal cell carcinoma (first line metastatic) - pazopanib: pre-meeting briefing
-
Renal cell carcinoma (first line metastatic) - pazopanib: pre-meeting briefing (PDF 317 KB)
-
Renal cell carcinoma (first line metastatic) - pazopanib: final scope
-
Renal cell carcinoma (first line metastatic) - pazopanib: final scope (PDF 54 KB)
-
Renal cell carcinoma (first line metastatic) - pazopanib: final matrix
-
Renal cell carcinoma (first line metastatic) - pazopanib: final matrix (PDF 58 KB)
-
Renal cell carcinoma (first line metastatic) - pazopanib: manufacturer submission
-
Renal cell carcinoma (first line metastatic) - pazopanib: manufacturer submission - submission
-
-
Renal cell carcinoma (first line metastatic) - pazopanib: manufacturer submission - systematic review
-
-
Renal cell carcinoma (first line metastatic) - pazopanib: clarification letters
-
Renal cell carcinoma (first line metastatic) - pazopanib: clarification letters - NICE request to the manufacturer for clarification on their submission
-
-
Renal cell carcinoma (first line metastatic) - pazopanib: clarification letters - manufacturer's response
-
-
Renal cell carcinoma (first line metastatic) - pazopanib: manufacturer submission Addendum
-
Renal cell carcinoma (first line metastatic) - pazopanib: manufacturer submission addendum
-
-
Renal cell carcinoma (first line metastatic) - pazopanib: Patient Access Scheme Submission
-
-
Renal cell carcinoma (first line metastatic) - pazopanib: clarification letters addendum
-
Renal cell carcinoma (first line metastatic) - pazopanib: NICE request to the manufacturer for clarification on their submission addendum
-
-
Renal cell carcinoma (first line metastatic) - pazopanib: Manufacturer's response to NICE's request for clarification
-
-
Renal cell carcinoma (first line metastatic) - pazopanib: patient group, professional group and NHS organisation submission
-
Renal cell carcinoma (first line metastatic) - pazopanib: Royal College of Nursing
-
Renal cell carcinoma (first line metastatic) - pazopanib: Royal College of Nursing (PDF 76 KB)
-
Renal cell carcinoma (first line metastatic) - pazopanib: Royal College of Physicians / NCRI / RCR / ACP / JCCO (joint submission)
-
-
Renal cell carcinoma (first line metastatic) - pazopanib: NHS Waltham Forest
-
Renal cell carcinoma (first line metastatic) - pazopanib: NHS Waltham Forest (PDF 53 KB)
-
Renal cell carcinoma (first line metastatic) - pazopanib: expert personal perspectives
-
Renal cell carcinoma (first line metastatic) - pazopanib: expert personal perspectives - Dr David Chao
-
-
Renal cell carcinoma (first line metastatic) - pazopanib: expert personal perspectives - Jacqueline Lowe
-
-
Renal cell carcinoma (first line metastatic) - pazopanib: expert personal perspectives - Dr Thomas Powles
-
-
Renal cell carcinoma (first line metastatic) - pazopanib: expert personal perspectives - Bill Savage
-
-
Renal cell carcinoma (first line metastatic) - pazopanib: Evidence Review Group report
-
Renal cell carcinoma (first line metastatic) - pazopanib: Evidence Review Group report (PDF 1.96 MB)
-
Renal cell carcinoma (first line metastatic) - pazopanib: Evidence Review Group report - factual accuracy check
-
-
Renal cell carcinoma (first line metastatic) - pazopanib: pro-forma response
-
Renal cell carcinoma (first line metastatic) - pazopanib: pro-forma response (PDF 42 KB)
Renal cell carcinoma (first line metastatic) - pazopanib: final scope
-
Renal cell carcinoma (first line metastatic) - pazopanib: final scope
-
Renal cell carcinoma (first line metastatic) - pazopanib: final scope (PDF 54 KB)
Renal cell carcinoma (first line metastatic) - pazopanib: Institute's response to consultee and commentator comments on the draft scope
-
Renal cell carcinoma (first line metastatic) - pazopanib: Institute's response to consultee and commentator comments on the draft scope
-
Renal cell carcinoma (first line metastatic) - pazopanib: Institute's response to consultee and commentator comments on the provisional matrix
-
Renal cell carcinoma (first line metastatic) - pazopanib: Institute's response to consultee and commentator comments on the provisional matrix
-
Renal cell carcinoma (first line metastatic) - pazopanib: provisional matrix
-
Renal cell carcinoma (first line metastatic) - pazopanib: provisional matrix
-
Renal cell carcinoma (first line metastatic) - pazopanib: provisional matrix (PDF 33 KB)
Renal cell carcinoma (first line metastatic) - pazopanib: draft scope
-
Renal cell carcinoma (first line metastatic) - pazopanib: draft scope
-
Renal cell carcinoma (first line metastatic) - pazopanib: draft scope (PDF 37 KB)